Cardiology

FDA accepted a priority review sNDA for mavacamten in adolescents with symptomatic obstructive hypertrophic cardiomyopathy.

Stay updated with the latest healthcare breakthroughs, including FDA approvals and phase 3 data.

Heather Johnson, MD, discusses progress in providing more individualized care to female cardiovascular patients, as well as what remains to be done.

Ferdinand shares his advice on high blood pressure management, drawing on his perspective as co-author of the ACC/AHA 2025 hypertension guidelines.

FDA De Novo classification clears Cardiosense PCWP Analysis Software to estimate filling pressures in selected adults with HFrEF.

Jason Guichard, MD, PhD, lead author of the study, discusses positive 2-year data from the investigative trial of the Cordella Pulmonary Artery Sensor System.

Lilly reports dose-dependent PCSK9 and LDL-C reductions with single-dose VERVE-102 in interim phase 1b hypercholesterolemia data.

Stay updated with the latest healthcare breakthroughs, including FDA approvals and phase 3 data.

Miedema highlights the shortcomings of current technology and medication for what is among the US’s fastest-growing and most devastating conditions.

Ashkan Shoamanesh, MD, discusses a series of abstracts presented at ESOC 2026 reinforcing asundexian’s protective effect in patients at risk of ischemic stroke or TIA.

Joshua Barrios, PhD, and Geoffrey Tison, MD, MSc, discuss their new AI echo’s comparative superiority in identifying cardiovascular disease.

Wilcox discusses the recent HFSA statement aiming to identify the unique characteristics of HFmrEF and define an alternative treatment pathway.

Deepak Bhatt, MD, MPH, MBA, discusses his recent presentation at the ASPC 2026 Virtual Imaging Symposium and how plaque imaging can change the MI landscape.

FDA granted priority review to asundexian for secondary prevention after non-cardioembolic ischemic stroke or TIA.

FDA approved baxdrostat as add-on therapy for adults with hypertension not controlled on other medications.

Stay updated with the latest healthcare breakthroughs, including FDA submissions and new cardiology guidelines.

Barry Borlaug, MD, discusses his recent publication collecting existing evidence on HFmrEF to reflect current data regarding treatment and management.

Marc Ruel, MD, MPH, discusses the progress made since in the 11 years since the last guidelines, both in treatment and therapy.

Payam Dehghani, MD, discusses his sub-study of the NACMI registry, following patients with COVID-19 and STEMI who survived to hospital discharge.

Pugazhendhi Vijayaraman, MD, discusses his recent presentation of the final results of LEADR LBBAP, simplifying the lead placement problems faced by earlier models.

Lucas Boersma, MD, PhD, discusses the 1-year results of the Enlighten study, highlighting effective defibrillation, low rate of complications, and high ATP success.

Mehdi Shishehbor, DO, PhD, discusses the 6-month results from his recent study, confirming the efficacy of the LimFlow System in patients with CLTI.

Erin Ferranti, PhD, MPH, discusses the new guidelines and their implications for continued enhancement of both access to and outcomes of postpartum care.

Sameh Sayfo, MD, discusses his recent analysis of the DETOUR2 study, highlighting the efficacy of the DETOUR system for patients regardless of runoff.

Bilchick discusses his recent study, highlighting a reduced risk of atrial fibrillation in patients taking prescription GLP-1 RAs irrespective of weight loss.